ReviewOncology research2026
Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review.
Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) breast cancer treatment has made a breakthrough due to the introduction of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. This article mainly reviews the mechanisms of action, clinical efficacy, and current application status of CDK4/6 inhibitors, including Palbociclib, Ribociclib, Abemaciclib, and the emerging Dalpiciclib. The advantages and limitations of different treatment stages are also discussed. CDK4/6 inhibitors have excellent efficacy in prolonging progression-free survival (PFS) and overall survival (OS), and have become a key option for HR+/HER2- breast cancer first-line and adjuvant treatment. The issues of drug resistance and adverse reactions remain severe. Strategies such as combining phosphoinositide 3-kinase (PI3K) inhibitors, immunotherapy, or new estrogen receptor (ER)-degrading agents are being actively explored for drug-resistant patients. The personalized precision therapy may become the core direction for optimizing the application of CDK4/6 inhibitors in the future, which will improve patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.